New Antiepileptic Drugs

Slides:

Advertisements

Similar presentations

What is Pharmacometrics (PM)?

Advertisements

Anticonvulsants David G. Standaert, MD, PhD Massachusetts General Hospital Harvard Medical School.

An Overview of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial-Onset Seizures Mark Versavel MD, PhD, MBA Vice President, Clinical Research.

Martha J. Morrell MD NeuroPace, Inc.

© 2013 Direct One Communications, Inc. All rights reserved. 1 Pharmacotherapy of Medically Refractory Partial-Onset Epilepsy Cynthia M. Correll, MD Emory.

CHOOSING THE RIGHT MEDICAL TREATMENT AND RECENT ADVANCES NEELIMA THAKUR, MD.

Eduardo Garcia, MD Assistant Clinical Professor

New Antiepileptic drugs Jacqueline A French MD NYU Comprehensive Epilepsy Center.

© 2015 Direct One Communications, Inc. All rights reserved. 1 The New Antiepileptic Drugs: Where Do They Belong in Our Armamentarium? Madhu Jasti, MD University.

Information prepared by Eisai Europe Ltd

New Antiepileptic Medications

© 2014 Direct One Communications, Inc. All rights reserved. 1 Update on Perampanel: A Novel Antiepileptic Drug for Partial-Onset Seizures Angela Wabulya,

© 2016 Direct One Communications, Inc. All rights reserved. 1 Recent Research Expands Our Understanding of Perampanel Christian M. Cabrera Kang, MD Emory.

Anticonvulsants By Alaina Darby.

Volume 92, Issue 2, Pages (December 2010)

Upfront Combination Therapy vs Step-Up Approach for PAH:

Long term effectiveness of perampanel: the Leeds experience Jo Geldard, Melissa Maguire, Elizabeth Wright, Peter Goulding Leeds General Infirmary, Leeds.

Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs)

Patient emotions and perceptions of antiepileptic drug changes and titration during treatment for epilepsy Jesse Fishman, Greg Cohen, Colin Josephson,

Pseudomonas Infection in Cystic Fibrosis

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.

To Titrate or Not: Optimizing Treatment With Antiepileptic Drugs

Neurostimulation for the Management of Medication-Resistant Epilepsy

Definitions: Seizure, Epilepsy, Epilepsy Syndrome

Management Considerations in Epilepsy Among Long-Term Care Residents

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

Transition of Care in Epilepsy Among Patients Entering Long-Term Care

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Lacosamide monotherapy for partial onset seizures

Severity of anxiety and depression are related to a higher perception of adverse effects of antiepileptic drugs Bety Gómez-Arias, Daniel Crail-Meléndez,

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Integrating Epilepsy Performance Measures Into Clinical Practice

New Antiepileptic Drugs

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

The Evolving Role of Immunotherapy in NSCLC

Novel Therapies for the Treatment of MS

Understanding Sudden Unexpected Death in Epilepsy

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

Glaucoma: Detect, Diagnose, And Monitor The Silent Thief of Vision

The future of urate-lowering strategies for gout

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Seizures in the Elderly: Treatment and Special Considerations

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

EHL Technologies in Hemophilia Care

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Managing Adverse Events With New Oral Therapies in CLL

Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Better Diabetes Control With Novel Basal Insulins

Updates in Seizure Management

Advancing Patient Care in RA

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Considerations in Managing Seizures in Women

Program Goals Disclaimers Defining Refractory Seizures.

The Changing Field of Melanoma: Ipilimumab.

Expert Perspectives in the Recognition and Management of Lennox-Gastaut Syndrome.

Managing Anemia in Lower-Risk MDS

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Preparing for Checkpoint Inhibitors in Breast Cancer

Novel Concepts in the Management of RCC

What Does the Future Hold and What Will It Mean for Patients?

Issues in Patients With Severe Epilepsy

Checkpoint Inhibitors in First-Line Advanced NSCLC

Updates on Dyslipidemia

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

“Anti Epileptic Drugs II”

Updates on Sickle Cell Disease

Assessing similarity of curves: An application in assessing similarity between pediatric and adult exposure-response curves July 31, 2019 Yodit Seifu,

Presentation transcript:

New Antiepileptic Drugs

Program Goals

Epilepsy Prevalence in the United States

Age and Prevalence of Epilepsy

Success in AED Regimens (%)

What Is Rational Polytherapy?

Proposed MOA of AEDs Enhance GABAergic Neuromodulation

Proposed MOA of AEDs Reduce Glutamate-Mediated Excitatory Modulation

Synergistic Drug Combinations

Lacosamide PK Profile

Lacosamide as Adjunctive Therapy Most Common TEAEs

Lacosamide Monotherapy Conversion Trial KM-Estimated 112-Day Exit Rate

Eslicarbazepine Acetate Approved as Monotherapy or Adjunctive Therapy for Patients With POS

Eslicarbazepine Pharmacokinetics

Eslicarbazepine as Adjunctive Therapy 50% or Greater Reduction in Seizure Frequency

Eslicarbazepine as Adjunctive Therapy Most Common TEAEs

Proposed MOA of AEDs

Perampanel

Perampanel for Refractory PGTC Seizures

New SV2A Modulators

Molecular Targets of AEDs Where Does This Leave Us?

Abbreviations

Abbreviations (cont)